Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K. Abou‐Alfa, Bruno Sangro, Vincent C. Tam et al.|NEJM Evidence|2022Cited by 1.4k
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.Ghassan K. Abou‐Alfa, Bruno Sangro, Stephen L. Chan et al.|Journal of Clinical Oncology|2022Cited by 398
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping PanelJason Willis, Justin I. Odegaard, Martina I. Lefterova et al.|Clinical Cancer Research|2019Cited by 237
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancerJ.E. Berchuck, Love Goyal, Francesco Facchinetti et al.|Annals of Oncology|2022Cited by 138
Circulating Tumor DNA Profiling of Advanced Biliary Tract CancersKabir Mody, Mitesh J. Borad, Pashtoon Murtaza Kasi et al.|JCO Precision Oncology|2019Cited by 86